GSK to expand respiratory pipeline with $1 4bn Aiolos Bio acquisition pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
GSK will pay $1 billion upfront and up to $400 million in certain success-based regulatory milestone payments. It will also make milestone payments as well as pay tiered royalties to China s Hengrui Pharma, which licensed the asthma therapy to Aiolos.
Founded in 2023, Aiolos is focused on developing therapies for respiratory and inflammatory conditions. It is currently developing 'AIO-001', a treatment for asthma which is ready to enter mid-stage clinical trials. The drug would expand the reach of its current respiratory biologics portfolio, including to the 40% of severe asthma patients with certain conditions, where treatment options are still needed, said Tony Wood, GSK's chief scientific officer.
GSK agrees $1 4 billion Aiolos Bio deal rte.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rte.ie Daily Mail and Mail on Sunday newspapers.
Merck KGaA, Hengrui Partner On Selective PARP1 Inhibitor And ADCs contractpharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from contractpharma.com Daily Mail and Mail on Sunday newspapers.